AstraZeneca
Institution - official statements with no named speaker · GBR
Track record: No forecast checked yet (14 not due, 52 being checked).
68forecasts & commitments on the record
29%can be checked as stated
38average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 64, stated on authority 3, educated guess 1.
Kinds of claim: forecast 63, mixed claim 2, speculation 2, commitment 1. · Download this report card as a picture
In the nine words
πρόγνωσιςInference from evidence62 · 91%μαντείαInspired knowledge3 · 4%εἰκασίαConjecture2 · 3%χρησμοδοσίαInstitutional delivery1 · 1%
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (68)
Core Tax rate is expected to be between 18-22%
of patients with CKD will be diagnosed by 2030, with associated
The Core Tax rate is expected to be between 18-22%
of plaintiffs is currently scheduled for May 2025.
dividend for FY 2024 will increase by $0.20 per share to $3.10 per
Launch of 20 new medicines expected by 2030
Company will be carbon zero for Scope 1 and 2 emissions and by 2030
sustained growth beyond 2030, the Company will continue investing
China has been submitted, with a decision expected in H2 2024.
maintain over 50 million trees worldwide by end of 2025, in
The Core Tax Rate is expected to be between 18-22%
dividend for 2023, payable on 11 September 2023, will be 11 August
approximately $1.9bn by the end of 2025.
expected to be substantially complete by the end of 2030, realising
are expected to be substantially complete by the end of 2025, with
announced that by the end of 2025, 95% of its key suppliers will
of new long-term debt, issued in May and June 2021, $4bn of term
dividend for 2022, payable on 12 September 2022, will be 12 August
attend a youth leadership summit in Tokyo in May 2022.
Health Organization (WHO), with c.80% of the doses going to low and
Tax will increase from 19% to 25% from 1 April 2023.
Results from the NAVIGATOR trial will be presented at this year's
dividend for 2021, payable on 13 September 2021, will be 13 August
will cease when the swap matures in 2021.
From 2021, AstraZeneca is likely to recognise
regulatory decision expected at the end of this year.
entity that, once fully operational in 2021, will mean that
business of IBOR reform will be assessed this year.
such the data readout is now expected in 2021.
patent no. 2568391 (expiry May 2025) related
dividend for 2020, payable on 14 September 2020, will be 14 August
2020, with an overall full completion of the building expected in
strategy up to 2025 and future reporting for 2019 onwards will
is expected that by 2022, the Companies entire US fleet will be
is expected that by 2022 our entire US fleet will be made up of
AstraZeneca expects the generic Crestor impact to recede significantly from 2019.
decision expected in the second half of 2019.
medicines are expected to be launched between 2014 and 2020, of
transaction is expected to close by the end of Q2 2018, subject to
will leave the EU on 29 March 2019 and relevant EU law and
trial results in 2019 that will further characterise the role of
will make regulatory submissions for Bevespi Aerosphere in Japan and China in 2018,
the original agreement will be made to AstraZeneca in 2018, if the
expected to be submitted for US regulatory review in 2018.
comparisons expected to ease in the second half of FY 2017, when
for 2016, payable on 20 March 2017, will be 17 February 2017.
Diabetes growth of 6% in the third quarter, reflecting an expected
Stockholm will trade ex-dividend from 10 August 2017.
The Company continues to anticipate EU approval in the first half of 2017.
A further payment of $1.5bn will be paid either on receipt of the first regulatory approval for acalabrutinib for any indication in the US, or the end of 2018, depending on which is first.
Showing the newest 50 - the ledger has all 68.